Aichi, Japan

Mikiko Morita


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mikiko Morita: Innovator in Pharmaceutical Chemistry

Introduction

Mikiko Morita is a prominent inventor based in Aichi, Japan. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target voltage-gated sodium channels. Her work is crucial for advancing treatments for various disorders and diseases.

Latest Patents

Mikiko Morita holds a patent for "Acyl piperazine derivatives as TTX-S blockers." This invention relates to acyl piperazine derivatives that exhibit blocking activities of voltage-gated sodium channels, specifically the TTX-S channels. These compounds are valuable in the treatment or prevention of disorders where voltage-gated sodium channels play a critical role. The patent also encompasses pharmaceutical compositions that include these compounds, highlighting their potential in medical applications.

Career Highlights

Throughout her career, Mikiko has demonstrated a strong commitment to innovation in the pharmaceutical industry. Her work at Raqualia Pharma Inc. has positioned her as a key player in the development of new therapeutic agents. With a focus on improving patient outcomes, she continues to explore the potential of her inventions in clinical settings.

Collaborations

Mikiko Morita collaborates with Shuzo Watanabe, a fellow researcher, to further enhance the impact of their work in the pharmaceutical field. Their partnership exemplifies the importance of teamwork in driving innovation and achieving breakthroughs in medical research.

Conclusion

Mikiko Morita's contributions to pharmaceutical chemistry, particularly through her patent on acyl piperazine derivatives, underscore her role as an influential inventor. Her ongoing work at Raqualia Pharma Inc. continues to pave the way for advancements in the treatment of diseases involving voltage-gated sodium channels.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…